Arbutus Biopharma (ABUS) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to 0.49%.

  • Arbutus Biopharma's Return on Capital Employed rose 1400.0% to 0.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.62% for FY2024, which is 900.0% down from last year.
  • Arbutus Biopharma's Return on Capital Employed amounted to 0.49% in Q3 2025, which was up 1400.0% from 0.57% recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Return on Capital Employed high stood at 0.33% for Q2 2022, and its period low was 0.79% during Q1 2025.
  • Its 5-year average for Return on Capital Employed is 0.51%, with a median of 0.49% in 2021.
  • In the last 5 years, Arbutus Biopharma's Return on Capital Employed skyrocketed by 9300bps in 2021 and then tumbled by -2100bps in 2023.
  • Over the past 5 years, Arbutus Biopharma's Return on Capital Employed (Quarter) stood at 0.42% in 2021, then grew by 7bps to 0.39% in 2022, then tumbled by -54bps to 0.61% in 2023, then decreased by -5bps to 0.63% in 2024, then increased by 22bps to 0.49% in 2025.
  • Its last three reported values are 0.49% in Q3 2025, 0.57% for Q2 2025, and 0.79% during Q1 2025.